A Phase 2b/3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig compared with placebo in adult participants with moderate-to-severe chronic obstructive pulmonary disease with type 2 inflammation.. (PERSEPHONE)

Principal Investigator

Dr Rob Hallifax

Contact us

Email: emcrf@ouh.nhs.uk

IRAS number

1012346